BNP Paribas Financial Markets
ENGN icon

BNP Paribas Financial Markets’s enGene Therapeutics ENGN Stock Holding History

BNP Paribas Financial Markets’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Buy
65,301
+29,424
+82% +$262K ﹤0.01% 3652
2025
Q4 		$324K Buy
+35,877
New +$287K ﹤0.01% 3813

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BNP Paribas Financial Markets's ENGN Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its enGene Therapeutics (ENGN) stake by 82% in Q1 2026, buying an estimated $262K and bringing the position to 65,301 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #3652.

BNP Paribas Financial Markets first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • BNP Paribas Financial Markets held 65,301 shares of enGene Therapeutics worth $445K as of Q1 2026.
  • BNP Paribas Financial Markets bought 29,424 enGene Therapeutics shares in Q1 2026, an estimated $262K.
  • enGene Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3652 holding.
  • BNP Paribas Financial Markets first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.